



Please join us for Celerion's Clinical Bioanalysis Discussion Forum Lunch

Scientific and Regulatory Considerations for the Bioanalysis of Biomarkers in a Regulated Environment

- "Context of Use" Framework for Biomarker Qualification
- Pre-Analytical Considerations and Technology Selection
- Assay Design, Development & Validation
- Case Studies Applying Context-of-use Framework

Event Details

Date: Tuesday, February 11, 2020

Time: 11:30-12:00: Registration & Networking

12:00-13:00: Presentation & Lunch 13:00-13:30: Q&A/Networking

Venue: Life Sciences Pennsylvania

650 East Swedesford Road, Suite 190

Wayne, PA 19087

RSVP

About The Speaker



Rafigul Islam | Executive Director, Bioanalytical Services

Rafiq Islam is the Executive Director of Bioanalytical Services at Celerion and responsible for the scientific and operational leadership of both small and large molecule bioanalysis, including bioanalytical and biomarker method development/validation and execution of sample analysis to support pharmacokinetic, immunogenicity, bioequivalence and biosimilar studies. Previously, he served as the Scientific Director for Biopharma Services at EMD Millipore. He held similar positions as the head of a bioanalytical department at Covance and Huntingdon Life Sciences. He also held several positions of increasing responsibility with Curagen Corporation. He has nearly 20 years of biotechnology industry experience.

About The Host



Celerion, a global leader in early clinical research services and clinical bioanalysis industry, offers a unique combination of medical expertise, clinical operations experience and scientific excellence that gives our clients the confidence to make fast, accurate decisions about their drug development path. Celerion uses our experience, agility and innovation to help clients get their drug to market faster so they can start making a difference in people's lives.

To access our unique insights for successful drug development, please visit: www.celerion.com